BioVie Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2023, compared with the three months ended September 30, 2022. Although the request metadata labels this “2023 Q1,” the filing covers the first quarter of BioVie’s fiscal year 2024. The financial statements are unaudited. BioVie is a clinical-stage, pre-revenue biopharmaceutical company.
Financial results and liquidity
| Metric | Quarter ended Sep. 30, 2023 | Quarter ended Sep. 30, 2022 / comparison |
|---|---|---|
| Revenue | None; the company reports no revenue and expects none in the foreseeable future. | No revenue reported. |
| Operating expenses | $10.9 million | $8.8 million; up about $2.1 million. |
| Research and development | $8.9 million | $6.8 million; up about $2.1 million. |
| Selling, general and administrative | $1.9 million | $2.0 million; down about $64,000. |
| Operating loss | $10.9 million | $8.8 million. |
| Net loss | $10.7 million; $0.29 per basic and diluted share | $10.4 million; $0.38 per share. |
| Net cash used in operating activities | $12.2 million | $9.2 million. |
| Cash and cash equivalents at period end | $21.2 million | $21.2 million at Sep. 30, 2022. |
| Working capital at period end | About $9.6 million | Not stated as a comparable figure. |
| Debt | $12.5 million remaining principal; $12.3 million net carrying amount | $2.5 million of principal repaid during the quarter. |
No meaningful operating margin is available because BioVie has no revenue. Interest income was $462,000, including a $223,865 realized gain on Treasury bill maturities. Net other income was $165,000, principally reflecting a $708,000 gain from the change in fair value of derivative liabilities; the comparable quarter had $1.6 million of net other expense. The loan carries a stated interest rate of the greater of prime plus 7% or 10.75%; its adjusted effective interest rate is reported as 25%. Principal payments began in July 2023, and the loan matures December 1, 2024.
Material changes and business developments
- R&D spending rose despite lower spending following completion of the Parkinson’s Phase 2 and ascites Phase 2b studies and near-completion of the Alzheimer’s Phase 3 trial. Management attributed the increase to next-study and other research activity, clinical-team and consultant costs, and conference-related expenses.
- The final patient completed the 30-week treatment in the NE3107 Alzheimer’s Phase 3 trial in late September 2023. Database cleaning was ongoing; management anticipated database lock, unblinding, and topline results in calendar Q4 2023.
- The NE3107 Parkinson’s Phase 2 study was completed in December 2022. The company said the study met its safety and efficacy objectives and was preparing for the next round of clinical studies.
- BIV201, an investigational continuous-infusion terlipressin treatment for ascites due to cirrhosis, has FDA Fast Track designation. The Phase 2b study closed before full enrollment; the company was discussing Phase 3 design with the FDA.
- BioVie raised $1.9 million net through its at-the-market equity sales agreement during the quarter. After quarter-end, it sold 819,935 shares for $3.5 million net. Shares outstanding were 36,899,880 at September 30, 2023; 37,742,695 were reported outstanding as of November 6, 2023.
Outlook, risks, and contingencies
- Going concern: The company states that planned operations are expected to deplete cash within 12 months of the balance-sheet date, even though cash might last that long if planned research and clinical expenditures are delayed. Management says additional capital is needed and that substantial doubt exists about the company’s ability to continue as a going concern. Funding may come from equity sales, loans, or strategic transactions; there is no assurance it will be available on acceptable terms. No financial statements adjustments for this uncertainty were recorded.
- Alzheimer’s trial integrity: During monitoring of blinded data, BioVie identified apparent potential scientific misconduct and significant GCP and regulatory non-compliance at six Phase 3 sites and notified the FDA’s Office of Scientific Integrity. Sensitivity analyses excluding those sites were incorporated into the statistical analysis plan, but the issues could undermine confidence in the full dataset or require additional studies.
- Financing and dilution: The company relies on equity financing and may issue more shares. Outstanding options, warrants, restricted stock units, a lender conversion feature, and potential milestone-related share issuances could dilute existing investors. Certain Acuitas warrants also have price-adjustment protections.
- Other risks: Clinical development, regulatory approval, third-party trial execution, access to capital, and access to cash held above federally insured limits are identified risks. The loan is secured by substantially all company assets, subject to exceptions.
- The filing provides no numerical revenue, profit, or cash-flow guidance. Management’s stated clinical timing is an expectation, not a guarantee. The company reported no material legal proceedings and no material changes to previously disclosed risk factors other than those described in the filing.
Important facts for investors to verify
- Whether NE3107 Alzheimer’s trial database lock, unblinding, and topline disclosure occurred as anticipated, and how the six-site integrity issues affect the analysis.
- Cash runway under planned clinical spending, the timing and terms of additional financing, and the effect of subsequent equity sales on dilution.
- The loan’s repayment schedule, remaining principal, maturity obligations, and potential lender conversion into shares.
- FDA feedback and a defined Phase 3 path for BIV201, along with the company’s plans and funding needs for further Parkinson’s studies.
- Whether the filing’s clinical, financing, and going-concern assumptions remain current in later company disclosures.